Aarti Drugs Q4 FY26 Earnings Call Transcript Released
Aarti Drugs released its Q4 FY26 earnings call transcript. Q4 FY26 revenue was ₹721.1 Cr (up 6% YoY), EBITDA ₹96.6 Cr (up 72% QoQ), and PAT ₹55.3 Cr (up 36% QoQ). Formulations revenue grew 41% YoY to ₹91.3 Cr. The company is ramping up its methylamine plant and targeting 8-10% volume growth with FY27 EBITDA margins of 13.5-14%. Capex of ₹300-400 Cr planned over 2-3 years.
The release of an earnings call transcript provides detailed insights into the company's financial performance, operational strategies, and future outlook. This information is crucial for investors and analysts to assess the company's trajectory, impacting investment decisions and market perception.
The announcement is a transcript of an earnings call. While it details financial performance and future outlook, it is a factual report of discussions and does not contain inherently positive or negative news beyond the reported results. The sentiment reflects the neutral nature of a transcript release.
Aarti Drugs Limited has released the transcript of its Q4 and FY26 Earnings Conference Call, which took place on May 18, 2026. The call featured management including Mr. Adhish Patil (COO & CFO), Mr. Harshit Savla (Joint Managing Director), and Mr. Harit Shah (Whole-Time Director).
During the call, management discussed the company's performance in FY26, describing it as an important execution year moving from investment to operational scale-up. Despite challenging industry conditions like global trade disruptions, pricing volatility, and elevated input costs due to geopolitical events, the company reported a sequential recovery in Q4 FY26. Operational initiatives such as process optimization and alternate sourcing helped mitigate pressures.
Consolidated financial highlights for Q4 FY26 showed revenue at ₹721.1 crores, a 6% year-on-year growth and 20% quarter-on-quarter growth. EBITDA stood at ₹96.6 crores, with a flat year-on-year growth and a 72% quarter-on-quarter increase. Profit After Tax (PAT) was ₹55.3 crores, a 12% year-on-year decrease but a 36% quarter-on-quarter increase.
The standalone business contributed 88% to consolidated revenue, with domestic revenue growing 7% year-on-year and export revenue declining 7% year-on-year. The formulation segment saw significant growth, with revenue at ₹91.3 crores in Q4 FY26, up 41% year-on-year, driven by exports which contributed 69% to this segment's revenue.
Key operational developments highlighted include the ramp-up of the new manufacturing facility for methylamines at Sayakha, which achieved a production rate of nearly 1,000 tonnes per month in March 2026. The company also noted an increasing contribution from regulated and export-oriented markets, with exports rising from 35% in FY25 to 38% in FY26.
Discussions also covered the salicylic acid business, where production was temporarily shut down due to equipment issues and raw material costs, with plans to restart after necessary improvements. The company is also exploring forward integration for salicylic acid derivatives. Management provided insights into capacity utilization targets for the methylamine plant and discussed the ongoing antidumping duty application for salicylic acid.
Looking ahead, the company aims for a volume growth of 8% to 10%, with internal targets of 10% to 15%. EBITDA margin targets for FY27 were set between 13.5% to 14%, with potential for improvement if crude prices remain stable. Capex plans of ₹300 crores to ₹400 crores over the next two to three years were outlined, focusing on expanding existing capabilities and formulation business.
What to do with a filing like this
Aarti Drugs Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Drugs Limited. Read the original for the full detail.